Anne Lesage, the Chief Early Development of $PHVS, sold 7,000 shares of the company on 04-22-2026 for an estimated $210,361. We received data on the trade from a recent SEC filing. This was a sale of approximately 11.0% of their shares of this class of stock. Following this trade, they now own 56,450 shares of this class of $PHVS stock.
$PHVS Insider Trading Activity
$PHVS insiders have traded $PHVS stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $PHVS stock by insiders over the last 6 months:
- BERNDT MODIG (Chief Executive Officer) has made 0 purchases and 3 sales selling 25,625 shares for an estimated $712,839.
- ANNE LESAGE (Chief Early Development) has made 0 purchases and 5 sales selling 14,700 shares for an estimated $441,725.
- PENG LU (Chief Medical Officer) has made 0 purchases and 2 sales selling 7,101 shares for an estimated $213,404.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$PHVS Hedge Fund Activity
We have seen 65 institutional investors add shares of $PHVS stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,835,494 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $50,934,958
- DEERFIELD MANAGEMENT COMPANY, L.P. added 683,578 shares (+28.0%) to their portfolio in Q4 2025, for an estimated $18,969,289
- VR ADVISER, LLC removed 674,599 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $18,720,122
- COMMODORE CAPITAL LP removed 529,031 shares (-21.9%) from their portfolio in Q4 2025, for an estimated $14,680,610
- EVERSEPT PARTNERS, LP added 439,177 shares (+inf%) to their portfolio in Q4 2025, for an estimated $12,187,161
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removed 379,194 shares (-11.9%) from their portfolio in Q4 2025, for an estimated $10,522,633
- BLACKROCK, INC. added 294,141 shares (+71.0%) to their portfolio in Q4 2025, for an estimated $8,162,412
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$PHVS Analyst Ratings
Wall Street analysts have issued reports on $PHVS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 12/04/2025
- Morgan Stanley issued a "Overweight" rating on 12/04/2025
- Wedbush issued a "Outperform" rating on 11/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for $PHVS, check out Quiver Quantitative's $PHVS forecast page.
$PHVS Price Targets
Multiple analysts have issued price targets for $PHVS recently. We have seen 8 analysts offer price targets for $PHVS in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- Andy Chen from Wolfe Research set a target price of $42.0 on 04/09/2026
- Laura Chico from Wedbush set a target price of $42.0 on 04/07/2026
- Brian Abrahams from RBC Capital set a target price of $51.0 on 04/06/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $60.0 on 03/03/2026
- Tazeen Ahmad from B of A Securities set a target price of $30.0 on 12/04/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $39.0 on 12/04/2025
- Matthew Harrison from Morgan Stanley set a target price of $41.0 on 12/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
